Media ReleasesNoxopharm

View All Noxopharm News


Noxopharm Releases Latest Corporate Presentation November 2018

Investment Highlights

Leader in the development of isoflavonoid-based therapeutics, an emerging field of drug development

- Novel family of G-protein inhibitors blocking key signaling pathways
- Key proprietary know-how on maximizing drug-like activity

Targeted applications across multiple therapeutic areas of high unmet need, including cancer, cardiovascular disease, neurodegenerative disease and autoimmune diseases

Commencing with Veyonda®, a sphingosine kinase inhibitor that boosts tumor response to chemotherapy and radiotherapy, major unmet needs

Targeting 2022 for revenue generation through commercialization of Veyonda® in first instance as radio-enhancer

Seasoned management and Board with deep public-company biotechnology experience

- Founder and CEO, Graham Kelly, previously founded NASDAQ-listed companies - Novogen Ltd and Marshall Edwards Inc (MEI Pharma Inc).


To view Presentation please download PDF attached: 
Download this document